ReviewEMBO molecular medicine2026
Pathobiology and clinical significance of malignant pleural effusions.
Review in EMBO molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Timing of definitive pleural intervention within systemic anticancer therapy in malignant pleural effusion from high-response lung cancers: a retrospective single-center cohort study.Translational lung cancer research · 2026Article
- Unraveling the multidimensional pleural ecosystem of lung cancer-associated malignant pleural effusion.Cancer cell international · 2026Review
- CXCL2/CXCR2 pathway regulates CD169Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Metastatic malignant pleural effusion (MPE) represents advanced-stage cancer and is defined by the establishment of metastatic tumor foci within the pleural space. It is most commonly associated with high degrees of morbidity and mortality. Annually, over 150,000 cancer patients in the United States develop MPE, which is associated with a dismal median survival of 3-12 months. As such, efforts must be made to understand the complex biological factors driving MPE pathophysiology. In this review, we discuss what is currently known and identify knowledge gaps regarding the intrinsic MPE biology of cancer cells and the heterotypic interactions between tumor cells and the immunologic pleural ecosystem. Furthermore, we discuss the clinical opportunities of studying MPE and identify promising directions for MPE research that may lead to a deeper understanding of the disease, ultimately aiming to enhance clinical outcomes for patients with advanced cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.